<DOC>
	<DOCNO>NCT00368875</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose vorinostat give together paclitaxel bevacizumab see well work treat patient metastatic breast cancer and/or breast cancer recur chest wall remove surgery . Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving vorinostat together paclitaxel bevacizumab may kill tumor cell .</brief_summary>
	<brief_title>Phase I-II Study Vorinostat , Paclitaxel , Bevacizumab Metastatic Breast Cancer</brief_title>
	<detailed_description>PRiMARY OBJECTIVES : I . To determine recommended phase II dose oral suberoylanilide hydroxamic acid ( vorinostat ) combination weekly paclitaxel bevacizumab patient chest wall recurrent metastatic breast cancer . ( Phase I ) II . To determine efficacy ( response rate , response duration , time disease progression , time treatment failure , overall survival ) toxicity oral suberoylanilide hydroxamic acid ( vorinostat ) combination weekly paclitaxel bevacizumab patient chest wall recurrent metastatic breast cancer . ( Phase II ) SECONDARY OBJECTIVES : I . To determine whether vivo treatment vorinostat induces ) acetylation proteins include histone H3 H4 , b ) ubiquitylation protein , c ) level p21 p27 level peripheral blood mononuclear cell ( pre treatment vs. cycle 1 day 2 3 VORINOSTAT dos prior paclitaxel . II . To determine whether vivo treatment vorinostat induces ) acetylation proteins include histone H3 H4 , ubiquitylation protein , c ) level Bim , Bak , tBID , p21 p27 level , well regulate Bcl-2 , Bcl-xL survivin chest wall recurrent metastatic breast cancer cell ( pre treatment vs. cycle 1 day 2 3 vorinostat dos prior paclitaxel ) . III . To determine whether primary breast cancer ( metastatic cancer available ) pretreatment level Her-2 , Estrogen Receptor ( ER ) -alpha , Progesterone Receptor ( PR ) , p21 , p27 , p-AKT , p-ERK1/2 , HDAC1 , 2 , 3 , 4 , 6 , 10 SIRT2 level predict response treatment VORINOSTAT plus paclitaxel . OUTLINE : This phase I , multicenter , dose-escalation study vorinostat ( SAHA ) follow phase II , open-label study . Phase I : Patients receive oral SAHA twice daily day 1-3 , 8-10 , 15-17 , paclitaxel IV 1 hour day 2 , 9 , 16 , bevacizumab IV 30-90 minute day 2 16 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos SAHA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . The recommended phase II dose define one dose level MTD . Phase II : Patients receive SAHA recommend phase II dose paclitaxel bevacizumab phase I .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>histologically cytologically confirm adenocarcinoma breast ; effective version 2.2 ( 1/26/09 ) , patient disease accessible biopsy consent serial biopsy eligible stage IV disease , locally recurrent inoperable chest wall disease ; least one bidimensional and/or unidimensional , measurable indicator lesion must present ( patient nonmeasurable disease eligible phase I trial ) ; sit disease note followed ECOG performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Absolute neutrophil count &gt; = 1,500/ul Platelets &gt; = 100,000/ul Total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) = &lt; 2.5 x institutional upper limit normal PTT either INR PT &lt; 1.5 x normal Creatinine within normal institutional limit OR creatinine clearance &gt; = mL/min/1.73 m^2 patient creatinine level institutional normal Urine protein screen urine analysis Urine Protein Creatinine ( UPC ) ratio ; UPC ratio &gt; 0.5 , 24hour urine protein obtain level &lt; 1000 mg patient enrollment ; LVEF must lower institutional limit normal range ( MUGA Echo obtain within 12 week registration , within 4 week prior Herceptin ) Not pregnant/lactating Exclusion criterion : chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study may receive investigational agent . history allergic reaction attribute compound similar chemical biologic composition vorinostat agent use study ( e.g. , paclitaxel , bevacizumab , quinolones ) uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>